Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

Inflammatory myofibroblastic tumor of the head and neck

verfasst von: Yan-Feng Chen, Wei-Dong Zhang, Ming-Wei Wu, Dian Ou-Yang, Quan Zhang

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm. The aim of this study was to enhance the understanding of head and neck IMT and to improve its diagnosis and management. Clinical features and related treatment of 10 IMT cases were retrospectively analyzed and the literature was reviewed. Tumor sites identified included four in the maxillary space, two in the buccal space, two in the parotid gland, one in the post aurem, and one in the neck. Nine of ten patients received local resection, and one of ten patients received a total maxillectomy. One patient had a local recurrence and died, while the other nine patients had no distant metastases and survived. A computed tomography (CT) exam performed on nine of the ten patients showed that six of these nine cases were heterogeneous in density, while the other three cases were homogeneous. Four cases showed marked heterogeneous enhancement, two cases showed mild heterogeneous enhancement, and three cases showed moderate homogeneous enhancement on contrast-enhanced CT images. The incidence of IMT in the head and neck is low, and local resection is currently the best treatment. A prolonged postoperative follow-up period is necessary for patients with IMT.
Literatur
1.
Zurück zum Zitat Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. Lyon: IARC Press; 2005. p. 150–1. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. Lyon: IARC Press; 2005. p. 150–1.
2.
Zurück zum Zitat Pettinato G, Manivel JC, De Rosa N, Dehner LP. Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol. 1990;94(5):538–46.PubMed Pettinato G, Manivel JC, De Rosa N, Dehner LP. Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol. 1990;94(5):538–46.PubMed
3.
Zurück zum Zitat Coindre JM. Histologic classification of soft tissue tumors (WHO, 1994). Ann Pathol. 1994;14(6):426–7.PubMed Coindre JM. Histologic classification of soft tissue tumors (WHO, 1994). Ann Pathol. 1994;14(6):426–7.PubMed
4.
Zurück zum Zitat Fang SH, Dong DJ, Jin M. Inflammatory myofibroblastic tumour of the maxillary sinus: CT appearance, clinical and pathological findings. Eur J Radiol Extra. 2006;60(1):5–9.CrossRef Fang SH, Dong DJ, Jin M. Inflammatory myofibroblastic tumour of the maxillary sinus: CT appearance, clinical and pathological findings. Eur J Radiol Extra. 2006;60(1):5–9.CrossRef
5.
Zurück zum Zitat Ribeiro AC, Joshi VM, Funkhouser WK, Mukherji SK. Inflammatory myofibroblastic tumor involving the pterygopalatine fossa. Am J Neuroradiol. 2001;22(3):518–20.PubMed Ribeiro AC, Joshi VM, Funkhouser WK, Mukherji SK. Inflammatory myofibroblastic tumor involving the pterygopalatine fossa. Am J Neuroradiol. 2001;22(3):518–20.PubMed
6.
Zurück zum Zitat Som PM, Brandwein MS, Maldjian C, Reino AJ, Lawson W. Inflammatory pseudotumor of the maxillary sinus: CT and MR findings in six cases. AJR Am J Roentgenol. 1994;163(3):689–92.PubMed Som PM, Brandwein MS, Maldjian C, Reino AJ, Lawson W. Inflammatory pseudotumor of the maxillary sinus: CT and MR findings in six cases. AJR Am J Roentgenol. 1994;163(3):689–92.PubMed
7.
Zurück zum Zitat Idrees MT, Huan Y, Woo P, Wang BY. Inflammatory myofibroblastic tumor of larynx: a benign lesion with variable morphological spectrum. Ann Diagn Pathol. 2007;11(6):433–9.PubMedCrossRef Idrees MT, Huan Y, Woo P, Wang BY. Inflammatory myofibroblastic tumor of larynx: a benign lesion with variable morphological spectrum. Ann Diagn Pathol. 2007;11(6):433–9.PubMedCrossRef
8.
Zurück zum Zitat Al-Sindi K, Al-Shehabi MH, Al-Khalifa SA. Inflammatory myofibroblastic tumor of paranasal sinuses. Saudi Med J. 2007;28(4):623–7.PubMed Al-Sindi K, Al-Shehabi MH, Al-Khalifa SA. Inflammatory myofibroblastic tumor of paranasal sinuses. Saudi Med J. 2007;28(4):623–7.PubMed
9.
Zurück zum Zitat Martines F, Martines E, Casamitjana CF, Perelló SE. Inflammatory myofibroblastic tumor of the larynx. Case report. An Otorrinolaringol Ibero Am. 2007;34(2):201–8.PubMed Martines F, Martines E, Casamitjana CF, Perelló SE. Inflammatory myofibroblastic tumor of the larynx. Case report. An Otorrinolaringol Ibero Am. 2007;34(2):201–8.PubMed
10.
Zurück zum Zitat Gale N, Zidar N, Podboj J, Volavšek M, Luzar B. Inflammatory myofibroblastic tumour of paranasal sinuses with fatal outcome: reactive lesion or tumour? J Clin Pathol. 2003;56(9):715–7.PubMedCrossRef Gale N, Zidar N, Podboj J, Volavšek M, Luzar B. Inflammatory myofibroblastic tumour of paranasal sinuses with fatal outcome: reactive lesion or tumour? J Clin Pathol. 2003;56(9):715–7.PubMedCrossRef
11.
Zurück zum Zitat Zitsch RP III, Pollak N, Loy TS. Management of inflammatory pseudotumor of the larynx. Otolaryngol Head Neck Surg. 2007;136(1):139–41.PubMedCrossRef Zitsch RP III, Pollak N, Loy TS. Management of inflammatory pseudotumor of the larynx. Otolaryngol Head Neck Surg. 2007;136(1):139–41.PubMedCrossRef
12.
Zurück zum Zitat Thomas L, Uppal HS, Kaur S, David VC. Inflammatory pseudotumour of the maxillary sinus presenting as a sino-nasal malignancy. Eur Arch Otorhinolaryngol. 2005;262(1):61–3.PubMedCrossRef Thomas L, Uppal HS, Kaur S, David VC. Inflammatory pseudotumour of the maxillary sinus presenting as a sino-nasal malignancy. Eur Arch Otorhinolaryngol. 2005;262(1):61–3.PubMedCrossRef
13.
Zurück zum Zitat Suh SI, Seol HY, Lee JH, Lee YH, Kim TK, Lee NJ, Woo JS, Kim IS. Inflammatory myofibroblastic tumor of the larynx. Head Neck. 2006;28(4):369–72.PubMedCrossRef Suh SI, Seol HY, Lee JH, Lee YH, Kim TK, Lee NJ, Woo JS, Kim IS. Inflammatory myofibroblastic tumor of the larynx. Head Neck. 2006;28(4):369–72.PubMedCrossRef
14.
Zurück zum Zitat Ma L, Wang K, Liu WK, Zhang YK. Is radical surgery necessary to head and neck inflammatory myofibroblastic tumor (IMT) in children? Childs Nerv Sust. 2009;25(3):285–91.CrossRef Ma L, Wang K, Liu WK, Zhang YK. Is radical surgery necessary to head and neck inflammatory myofibroblastic tumor (IMT) in children? Childs Nerv Sust. 2009;25(3):285–91.CrossRef
Metadaten
Titel
Inflammatory myofibroblastic tumor of the head and neck
verfasst von
Yan-Feng Chen
Wei-Dong Zhang
Ming-Wei Wu
Dian Ou-Yang
Quan Zhang
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9729-3

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.